Orbimed Advisors LLC Ventyx Biosciences, Inc. Transaction History

Orbimed Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.9 - $10.13 $3.55 Million - $18.9 Million	1,870,456 New	1,870,456 $10.3 Million
Q3 2023 Nov 14, 2023	SELL	$29.8 - $40.3 $5.98 Million - $8.08 Million	-200,600 Reduced 37.08%	340,384 $11.8 Million
Q2 2023 Aug 14, 2023	SELL	$28.53 - $39.55 $1.26 Million - $1.74 Million	-44,016 Reduced 7.52%	540,984 $17.7 Million
Q1 2023 May 15, 2023	SELL	$29.51 - $46.65 $10 Million - $15.9 Million	-340,000 Reduced 36.76%	585,000 $19.6 Million
Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $16.9 Million - $25.5 Million	700,000 Added 311.11%	925,000 $30.3 Million
Q3 2022 Nov 14, 2022	SELL	$12.64 - $38.7 $13.5 Million - $41.2 Million	-1,064,280 Reduced 82.55%	225,000 $7.86 Million
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $18.3 Million - $29.7 Million	1,289,280 New	1,289,280 $25.6 Million

124

57.4M

222K

269K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $131M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.